Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (at least 18 years old)~* Plasma HIV RNA \> 1000 copies/ml~* HIV-1-infection confirmed by ELISA and Western blot or Immunofluorescence~* ART naïve patients or~* ART for less than 3 months and more than 6 months ago ; an HIV resistance genotype at baseline showing no mutation to NNRTI and TDF or 3TC will be required~* For women of childbearing age, negative urinary test for pregnancy and to accept contraceptive methods: condom use and intra-uterine device when possible or declare no wish of pregnancy in the coming year.~* Confirmed or probable TB~* TB treatment including rifampin started since 2 to 8 weeks before randomisation~* Signed informed consent form~* For French patients, to be affiliated to the National Health Care System~Exclusion Criteria:~* HIV-2 infection (single or with HIV-1)~* Woman who is pregnant or likely to become so, is breastfeeding or refuses to use contraception~* ALT\>2.5N, Hb \<7g/dl, neutrophils \< 750/mm3, platelet\<50 000/mm3, bilirubin \>5N, lipase \>3N~* Creatinine clearance \<60ml/min as assessed by the Cockcroft method~* Ongoing psychiatric pathology or any condition (including, but not limited to, the consumption of alcohol or drugs) which might, in the investigator's opinion, compromise the safety of treatment and/or patient compliance with the protocol~* Concomitant treatments including phenytoin or phenobarbital (compounds interacting with UGT1A1)~* Prior TB with a Mycobacterium tuberculosis strain resistant to rifampin~* TB treatment started for more than 8 weeks before randomisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): efavirenz
- 2 (Type: EXPERIMENTAL): raltegravir 400 mg
- 3 (Type: EXPERIMENTAL): raltegravir 800 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).